Primary Manuscripts
Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United States
Liu AY, Dominguez Islas C, Gundacker H, Neradilek B, Hoesley C, van der Straten A, Hendrix CW, Beamer M, Jacobson CE, McClure T, Harrell T, Bunge K, Devlin B, Nuttall J, Spence P, Steytler J, Piper JM, Marzinke MA; MTN-036/IPM 047 Protocol Team for the Microbicide Trials Network. Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United States. J Int AIDS Soc 2021 Jun;24(6):e25747. PMCID: PMC8196716
Other Key Manuscripts
Acceptability and Preference for 3-Month Versus 1-Month Vaginal Rings for HIV-1 Risk Reduction Among Participants in a Phase 1 Trial
Roberts ST, Hawley I, Luecke E, Mensch B, Wagner T, Hoesley C, McClure T, Dominguez Islas CP, Piper JM, Liu AY, van der Straten A. Acceptability and Preference for 3-Month Versus 1-Month Vaginal Rings for HIV-1 Risk Reduction Among Participants in a Phase 1 Trial. J Womens Health (Larchmt) 2022 Jul;31(7):1029-1039. PMCID: PMC9299526
Users' Preferred Characteristics of Vaginal Rings for HIV Prevention: A Qualitative Analysis of Two Phase I Trials
Hawley I, Song M, Scheckter R, McClure T, Piper J, Chen B, Hoesley C, Liu A, van der Straten A. Users' Preferred Characteristics of Vaginal Rings for HIV Prevention: A Qualitative Analysis of Two Phase I Trials. AIDS Res Hum Retroviruses 2022 Apr;38(4):313-326. PMCID: PMC9048173